MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Jun 05, 2023
May 22, 2023
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
May 18, 2023
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Amendment to a previously filed DRS
Data provided by Kaleidoscope.
Events and Presentations
June 13, 2023 at 10:30 AM EDT
May 11, 2023 at 8:30 AM EDT
April 20, 2023 at 10:00 AM EDT